Therefore, we expect that targeting VEGF222/NF should inhibit the three major hallmarks of cancer: tumour cell proliferation, angio/lymphangiogenesis and immune tolerance at an advanced/metastatic stage of tumour development. The gene discussed is NFASC; the disease is neoplasm.